NCT06926816

Universal Genetic Testing for Cancer Risk Reduction

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 600 (estimated)
• Sponsor: NYU Langone Health · Academic / Other
• Sex: Female
• Age: 25 Years – 39 Years
• Healthy volunteers: Accepted

Summary

The purpose of this research study is to see if offering genetic testing for cancer-related genes is feasible and acceptable for patients presenting for gynecology clinic visits, instead of needing to see specialized providers or needing to meet specific criteria. The primary aim to assess the proportion of patients who undergo genetic testing, and the proportion of patients with pathogenic variants.

Conditions

• Genetic Testing

Interventions

Type	Name	Description
GENETIC	Natera® Empower™ hereditary cancer panel test	The test will be the Natera® Empower™ hereditary cancer panel test and will be collected by saliva.
OTHER	Specialist Referral	Participants with actionable pathogenic variants will be referred to the appropriate specialists (e.g., medical oncologist, gynecologic oncologist, breast surgeon) to discuss risk-reduction strategies and offered genetic counseling

Timeline

• Start date: 2025-03-04
• Primary completion: 2026-12-31
• Completion: 2027-12-31
• First posted: 2025-04-15
• Last updated: 2026-03-02

Locations

1 site across 1 country: United States